2013
DOI: 10.1093/jnci/djt205
|View full text |Cite
|
Sign up to set email alerts
|

Investigation of Complement Activation Product C4d as a Diagnostic and Prognostic Biomarker for Lung Cancer

Abstract: Complement fragment C4d may serve as a biomarker for early diagnosis and prognosis of lung cancer.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

9
126
1
2

Year Published

2015
2015
2023
2023

Publication Types

Select...
4
3
1

Relationship

0
8

Authors

Journals

citations
Cited by 133 publications
(140 citation statements)
references
References 29 publications
9
126
1
2
Order By: Relevance
“…The utility of proteins as biomarkers in both targeted and surrogate tissue to reflect an individual's current health status has long been used in clinical settings as diagnostic and predictive tests. Plasma and serum are a matrix of protein, RNA, microRNA, and DNA, making them an ideal sources for biomarker discovery [5,[13][14][15]. Identification of these proteins not only provides information in understanding the mechanisms that can account for lung cancer development, but also in providing biomarkers to monitor disease progression [16].…”
Section: Significance Of the Studymentioning
confidence: 99%
“…The utility of proteins as biomarkers in both targeted and surrogate tissue to reflect an individual's current health status has long been used in clinical settings as diagnostic and predictive tests. Plasma and serum are a matrix of protein, RNA, microRNA, and DNA, making them an ideal sources for biomarker discovery [5,[13][14][15]. Identification of these proteins not only provides information in understanding the mechanisms that can account for lung cancer development, but also in providing biomarkers to monitor disease progression [16].…”
Section: Significance Of the Studymentioning
confidence: 99%
“…Cependant, de récentes études semblent contredire ce paradigme en montrant que le système du complément peut être relié à des effets pro-tumoraux. L'expression anormale de protéines du complément a été révélée dans de nombreux types de tumeurs, notamment dans des tumeurs du poumon [11], du sein [12], du pancréas [13], du rein [14] et urothéliales (vessie et haut appareil urinaire) [15]. Parmi ces protéines, le C1q, le C1s, le C3, le C4, les anaphylatoxines C3a et C5a, et leurs récepteurs, ainsi que les protéines régulatrices comme le facteur B, facteur H, facteur I, CD46, CD55 et CD59, sont le plus souvent surexprimées.…”
Section: Protéines Du Complément Et Contexte Tumoralunclassified
“…En fonction du type de cancer considéré, l'impact du système du complément peut en effet varier en ce qui concerne les protéines impliquées, mais également en termes de valeur pronostique. Dans la majorité des cancers, comme le cancer du rein [14], du sein [12], du poumon [11], de l'ovaire [18] et urothéliales [15], les protéines du complément favorisent la croissance tumorale. Dans d'autres, comme le cancer de la prostate [19], ces protéines n'ont aucune influence sur la croissance tumorale, elles peuvent même la ralentir.…”
Section: Protéines Du Complément Et Contexte Tumoralunclassified
“…Elevated levels of C3a are present in the ascitic fluid of patients with ovarian cancer (Bjorge et al, 2005). C3c and C4 levels are elevated in lung cancer patients and their concentration is directly correlated with tumor volume (Ajona et al, 2013(Ajona et al, , 2015. The lectin pathway of Complement is more activated in colorectal cancer patients in comparison to healthy individuals, and systemic levels of MASP-2 have been reported to be an independent prognostic marker for poor survival (Ytting, Jarle Christensen, Thiel, Jensenius, & Nielsen, 2005).…”
Section: Macrophages In Complement-mediated Ptx3-regulated Tumor Promentioning
confidence: 99%